Effect of PRM-125 on Ambulatory Blood Pressure
Primary Purpose
Hypertension
Status
Withdrawn
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
PRM-125
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- primary hypertension
Exclusion Criteria:
- medical conditions that preclude evaluation and/or adversely effect subject safety
Sites / Locations
- AMR
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PRM125
Arm Description
PRM125
Outcomes
Primary Outcome Measures
Change in 24 hour Systolic Blood Pressure
Secondary Outcome Measures
Change in 24 hour Diastolic Blood Pressure
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05195827
Brief Title
Effect of PRM-125 on Ambulatory Blood Pressure
Official Title
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults With Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor
Study Start Date
December 20, 2021 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
November 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PRM Pharma, LLC
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension
Detailed Description
Approximately 60 subjects with primary hypertension are treated for 8 weeks with PRM125 to determine if Ambulatory Blood Pressure is changed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PRM125
Arm Type
Experimental
Arm Description
PRM125
Intervention Type
Drug
Intervention Name(s)
PRM-125
Intervention Description
Antihypertensive
Primary Outcome Measure Information:
Title
Change in 24 hour Systolic Blood Pressure
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change in 24 hour Diastolic Blood Pressure
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
primary hypertension
Exclusion Criteria:
medical conditions that preclude evaluation and/or adversely effect subject safety
Facility Information:
Facility Name
AMR
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of PRM-125 on Ambulatory Blood Pressure
We'll reach out to this number within 24 hrs